ÍÆ¼ö¸øºÃÓÑ ÉÏһƪ | ÏÂһƪ

CTÒýµ¼Ï¾­Æ¤´©´Ì»î¼ìÔڷβ¿¼²²¡Õï¶ÏÖеļÛÖµ

CTÒýµ¼Ï¾­Æ¤´©´Ì»î¼ìÔڷβ¿¼²²¡Õï¶ÏÖеļÛÖµ

ÕÔ´ó±ø Àî¹â Áõ½¹Ö¦ Ðì·å ¶­ÓÓºì ¹ËÎÀƽ Ñîȫϲ
¡¾ÕªÒª¡¿¡¡Ä¿µÄ¡¡ÆÀ¼ÛCTÒýµ¼Ï¾­Æ¤·Î´©´Ì»î¼ì¶Ô·Î²¿¼²²¡µÄÕï¶Ï¼ÛÖµ¼°²¢·¢Ö¢¡£·½·¨¡¡ÔÚCTÒýµ¼ÏÂʹÓÃÈ«×Ô¶¯ÇиîÕë¶Ô76Àý·Î²¿¾ÖÏÞÐÔ²¡Ô¾ÖÏÞÐÔ²¡Ôî×é--A×飩ºÍ7Àý·Î²¿ÃÖÂþÐÔ²¡ÔÃÖÂþÐÔ²¡Ôî×é--B×飩Ðо­Æ¤·Î´©´Ì»î¼ì£»·ÖÎöÆä´©´Ì³É¹¦Âʼ°²¡Àíѧ×ÊÁÏ£»¹Û²ìÆøÐØºÍ¿©ÑªµÄ·¢Éú¡£½á¹û¡¡´©´ÌÎﲡÀíѧ×ÊÁÏÏÔʾ£¬2×é¹²ÓÐ79Àý³É¹¦´©´Ì»î¼ìµ½²¡Ôî×éÖ¯£»·Î´©´Ì³É¹¦ÂÊ¡£A×é´©´Ì³É¹¦ÂÊ(98.7% )¸ßÓÚB×é(57.1% ) ( P < 0.01) ¡£A×é·Î°©Õ¼76.3% (58 /75)£»B×é·Î°©Õ¼28.6% (2 /7)£»¶þ×é²îÒìÓÐͳ¼ÆÑ§ÒâÒå( P< 0.01) ¡£ºÏ¼ÆÁ½×é·Î²¿²¡ÔîÁÙ´²×ÜÈ·ÕïÂÊΪ95.2% (79/83)¡£Á½×éºÏ¼Æ·¢ÉúÆøÐØ23Àý£»¿©Ñª17Àý¡£½áÂÛ¡¡CTÒýµ¼Ï¾­Æ¤·Î´©´Ì»î¼ì²Ù×÷¼òµ¥¡¢¿É¿¿£¬×é֯ѧ±ê±¾»ñÈ¡Âʼ°²¡ÀíѧÕï¶ÏÂʸߣ¬µ«ÆøÐØ¡¢¿©ÑªµÈ²¢·¢Ö¢·¢ÉúµÄ·çÏÕÈÔ´æÔÚ¡£
[¹Ø¼ü´Ê]  ·Î¼²²¡/Õï¶Ï£»´©´ÌÊõ£»»î×éÖ¯¼ì²é£»Ìå²ãÉãÓ°Êõ£¬XÏß¼ÆËã»ú
The diagnostic value of CT-guided percutaneous transthoracic needle biopsy in patients with pneumonic diseases
ZHAO Dabing, LI Guang, LIU Jiaozhi, XU Feng, DONG Youhong, ZHAO Chuanjun, GU Weiping
The Xiangfan First Hospital, Jiefang road 75, Fancheng District, Xiangfan 441000, Hubei Province, China
[Abstract]  Objective To explore the diagnostic value and complication of percutaneous CT-guided lung biopsy for pulmonary lesions. Methods  CT-guided percutaneous transthoracic needle biopsy was carried out in 83 consecutive patients with pneumonic diseases dated from Dec 2007 to Aug 2008, followed by pathological examinations. Accuracy, pathologic data was analyzed in all cases. Results 79 out of 83 cases were performed successfully, and 60 cases of 79 were proved to be lung cancer. The complications included mild pneumothorax (n =23), and small hemop tysis (n = 17). All complications didn¡¯t represent the need for medical specific treatment. Conclusion CT-guided percutaneous needle biopsy in pneumonic diseases is a safe and effective diagnostic means, which has a high diagnostic rate and few complications. Its accuracy relates to the size of the target lesion.
[Key words]  CT-guided; percutaneous biopsy; lung neoplasm;needle aspiration; diagnosis


 

·Î²¿²¡±äµÄÓ°Ïñ¼ì²éÓжàÖÖ, µ«¶¨ÐÔÕï¶ÏÈÔÓÐÒ»¶¨ÄѶȡ£Ëæ×ÅÖ×ÁöÖÎÁƵĽøÕ¹£¬ÖÎÁÆ·½°¸µÄºÏÀíÔËÓÃÓÐÀµÓÚ²¡ÀíѧÕï¶Ï¡£CTÒýµ¼Ï¾­Æ¤·Î´©´Ì»î¼ìÊÇÒ»ÖÖÓÐЧ¡¢Î¢´´µÄ¶¨ÐÔ·½·¨£¬ÆøÐغͿ©ÑªÊÇÆäÖ÷Òª²¢·¢Ö¢[1]¡£±¾ÎĶÔ76Àý·Î²¿¾ÖÏÞÐÔ²¡ÔîºÍ7Àý·Î²¿ÃÖÂþÐÔ²¡Ôî½øÐÐÁ˾­Æ¤·Î´©´Ì»î¼ì£¬Ö¼ÔÚͨ¹ý´©´ÌÎﲡÀíѧ×ÊÁÏ·ÖÎöºÍ²¢·¢Ö¢¹Û²ì£¬ÆÀ¼ÛCTÒýµ¼Ï¾­Æ¤´©´Ì»î¼ìÔڷβ¿¼²²¡Õï¶ÏÖеļÛÖµ¼°°²È«ÐÔ¡£
²ÄÁÏÓë·½·¨
1.1 Ò»°ã×ÊÁÏ
83Àý²¡Àý£¬¾ùϵ2007Äê12Ô¡«2008Äê8ÔÂסԺ»¼Õߣ¬ÄÐ62Àý¡¢Å®21Àý£¬ÄêÁä17-80Ëê¡£¸ù¾Ý·Î²¿²¡ÔîÓ°Ïñѧ±íÏÖ·ÖΪA¡¢BÁ½×é¡£A×éΪ¾ÖÏÞÐÔ²¡Ôî×飬76Àý¡£B×éΪÃÖÂþÐÔ²¡Ôî×飬7Àý¡£A×é9Àý¡¢B×é1ÀýÓڷδ©´ÌǰÒÑÐÐÏËÎ¬Ö§Æø¹Ü¾µ¼ì²é£¬Î´ÄÜÃ÷È·Õï¶Ï¡£
1.2 ´©´ÌÆ÷²ÄºÍ·½·¨
´©´ÌÆ÷²ÄΪÃÀ¹úBARD¹«Ë¾Éú²úµÄÈ«×Ô¶¯»î¼ìǹ¼°»î¼ìÕë(18G»ò20G)£¬Òýµ¼ÒÇÆ÷ΪµÂ¹úsiemens¼°ÃÀ¹úGE¹«Ë¾ÂÝÐýCTɨÃèÒÇ£©¡£
¸ù¾Ý²¡±äµÄ²¿Î»£¬»¼Õß¿ÉÑ¡ÓÃÑöÎÔλ¡¢¸©ÎÔλ¡¢²àÎÔλ3ÖÖÌåλ¡£ÏÈɨȡ¶¨Î»Ïñ£¬È·¶¨Òª´©´Ì²¡±äÇøÓò(°ÐÇø) £¬¸ù¾Ý°ÐÇø´óС£¬Éè²ãºñ5 mm»ò3 mm£¬Á¬ÐøÉ¨6¡«12²ã£¬²âÁ¿°ÐÇøµÄ×î´ó¾¶£¬½èÖúCT»úÅ䱸µÄ¼¤¹âÌå±í¶¨Î»ÒǼ°CTͼÏñ£¬È·¶¨´©´Ì½øÕëµã¡¢·½ÏòºÍÉî¶È¡£´©´Ì;¾¶±Ü¿ª¹Ç÷À¡¢Éñ¾­¡¢´óѪ¹Ü¡¢·Î´óÅݺͻµËÀÇøµÈ¡£¶¨Î»ºó£¬³£¹æÏû¶¾¡¢ÆÌ½í¡¢¾ÖÂ飬°´É趨·¾¶½øÕëÖÁÔ¤¶¨²¿Î»ºó£¬ÔÙ´ÎÐв¡ÔλCTɨÃ裬ȷ¶¨ÕëÍ·½øÈë°ÐÇø±ßÔµ£¬¿Û¶¯°â»ú£¬ÐÐ×Ô¶¯Çиȡ²Äºó£¬ÏȽ«ËùÈ¡×éÖ¯ÌõÔÚ²£Æ¬ÉϹö¶¯£¬ÒÔÌáȡϸ°û£¬ËÍϸ°ûѧ¼ì²é£»½«½Ï´ó×éÖ¯Ìõ¾­10%¼×È©¹Ì¶¨ºóËÍ×é֯ѧ¼ì²é¡£Öظ´ÉÏÊö²Ù×÷2-3´Î£¬ÒÔÌá¸ß¼ì²é³É¹¦ÂÊ¡£
1.3¡¡ÆøÐع۲ì
´©´ÌÍê±Ïºó¼´¿ÌÐÐÈ«ÐØ²¿CTɨÃ裬ÒÔÃ÷È·ÊÇ·ñ³öÏÖÆøÐؼ°ÆøÐصij̶ȡ£CTɨÃèδ¼ûÆøÐØµÄ»¼Õߣ¬ÔÚ·µ»Ø²¡·¿ºó¼ÌÐø¹Û²ì24 h£¬Èç³öÏÖºôÎüÀ§ÄÑ£¬ÔòÐÐÐØ²¿Í¸ÊÓ»òÉãÐØ²¿XÏ߯¬£¬ÒÔÃ÷È·ÊÇ·ñ·¢ÉúÆøÐØ¡£¶ÔÓÚÉÙÁ¿ÆøÐØ£¬¸øÓèÆ½ÎÔ¡¢ÎüÑõµÈ´¦Àí£¬Ò»°ã²»¸øÓèÐØÇ»±ÕʽÒýÁ÷´¦Àí¡£
1.4¡¡¿©Ñª¹Û²ì
½«·Î´©´ÌÊõºó24 hÄÚгöÏֵĿ©Ñª»ò¿©ÑªÁ¿Ã÷ÏÔÔö¶àÊÓΪ´©´ÌÒýÆðµÄ¿©Ñª¡£ÔÚ´©´ÌǰÒÑÓÐÉÙÁ¿¿©ÑªÖ¢×´ÇÒ´©´ÌÊõºó¿©ÑªÁ¿ÎÞÃ÷ÏÔÔö¶àµÄ²¡Àý(A×é10Àý£¬B×é2Àý)£¬²»×÷±¾ÎĵĿ©ÑªÍ³¼Æ¡£¶ÔÓÚ¿©ÑªÁ¿½Ï¶à»¼Õß¾ù¸øÓèֹѪ¡¢¿¹ÉúËØÔ¤·À¸ÐȾµÈ´¦Àí¡£
1.5¡¡Í³¼ÆÑ§´¦Àí
ʹÓæÖ2¼ìÑé¶ÔÁ½×黼Õß´©´Ì³É¹¦ÂÊ¡¢·Î°©¼ì³öÂÊ¡¢ÆøÐؼ°¿©Ñª·¢ÉúÂʽøÐбȽϡ¢·ÖÎö¡£
½á¹û
2.1  ϸ°ûѧ¼°×é֯ѧ½á¹û
´©´ÌÎïϸ°ûѧ¼°×é֯ѧ½á¹ûÏÔʾ£¬A×é»î¼ìµ½²¡Ôî×éÖ¯(´©´Ì³É¹¦) 75 Àý£¬³É¹¦ÂÊ98.7% ( 75/76)¡£B×é´©´Ì³É¹¦4Àý£¬³É¹¦ÂÊ57.1% (4/7)Ö¯¡£Á½×é´©´Ì³É¹¦ÂÊÓÐÏÔÖøÐÔ²îÒì(P<0.01) ¡£Á½×éºÏ¼Æ´©´Ì³É¹¦ÂÊ95.2% (79/83)¡£A×éÖУ¬²¡Àí½á¹ûΪ·Î°©58Àý£¨Õ¼76.3%£¬ÆäÖÐÏÙ°©34Àý£¬ÁÛ°©16£¬ÏÙÁÛ°©5Àý£¬Ï¸Ö§Æø¹Ü·ÎÅݰ©3Àý£©£¬½áºËÁö8Àý£¬Ó²»¯ÐÔѪ¹ÜÁö6Àý£¬ÏÙÁö3Àý¡£B×éÖÐÏ¸Ö§Æø¹Ü·ÎÅݰ©2Àý£¬Õ¼28.6% (2/7)£¬ÓëA×é·Î°©¼ì³öÂʱȽÏÓÐÏÔÖøÐÔ²îÒì(P<0.01)£»2Àý²¡Àí½á¹ûΪ·Î×éÖ¯ÏËά»¯¼°ÂýÐÔÑ×ϸ°û½þÈ󣬽áºÏÁÙ´²±íÏÖ£¬1ÀýÈ·ÕïÎªÌØ·¢ÐԷμäÖÊÏËά»¯£¬1ÀýÈ·ÕïΪÂýÐÔÖ§Æø¹ÜÑס£ºÏ¼ÆÁ½×é·Î²¿²¡Ôî×ÜÈ·ÕïÂÊΪ95.2% (79/83)¡£
2.2¡¡²¢·¢Ö¢
¢ÙÆøÐØ¡¡A×é·¢ÉúÆøÐØ21Àý£¬·¢ÉúÂÊ27.6% (21/76) £¬B×é·¢ÉúÆøÐØ2Àý£¬·¢ÉúÂÊ28.6%£¨2/7£©£¬¶þ×éÆøÐØ·¢ÉúÂÊÎÞÏÔÖøÐÔ²îÒì(P>0.05)¡£ºÏ¼ÆÁ½×éÆøÐØ·¢ÉúÂÊΪ27.7% (23/83) ¡£Á½×éÆøÐØ»¼Õß¾ùδ½ÓÊÜÐØÇ»´©´Ì³éÆø»ò±ÕʽÒýÁ÷£¬ÆøÐØÈ¬Óú¡£
¢Ú¿©Ñª¡¡A×é·¢Éú¿©Ñª15Àý(ÁíÍâ4ÀýÓڷδ©´ÌǰÒÑÓÐÉÙÁ¿¿©ÑªÇÒÊõºó¿©ÑªÁ¿ÎÞÃ÷ÏÔÔö¶à£¬²»×÷¿©ÑªÍ³¼Æ)£¬·¢ÉúÂÊ19.8% (15/76)¡£B×é·¢Éú¿©Ñª(ÉÙÁ¿) 2Àý£¬·¢ÉúÂÊ28.6% (2/7)¡£Á½×鿩Ѫ·¢ÉúÂʲîÒìÎÞͳ¼ÆÑ§ÒâÒå(P> 0.05)£¬2×éºÏ¼Æ¿©Ñª·¢ÉúÂÊΪ20.5% (17/83)¡£
ÌÖÂÛ
·Î²¿²¡±ä»ñµÃ²¡ÀíѧÒÀ¾ÝµÄ³£¹æ·½·¨ÓÐÏËÖ§¾µ»î¼ì£¬¶ÔÓÚÖÜΧÐÍ»òÃÖÂþÐͷβ¿²¡±ä»¹ÓÐÐØÇ»¾µ»î¼ìºÍC TÒýµ¼Ï¾­Æ¤·Î´©´Ì»î¼ì¡£C T Òýµ¼Ï·β¿²¡±ä´©´Ì»î¼ìÊõ, ÊÇÒ»ÖÖ°²È«¡¢¾­¼Ã¡¢×¼È·¡¢´´ÉËÐÔСµÄ»î¼ì·½·¨¡£
3.1·Î²¿¾ÖÏÞÐÔ²¡Ôî´©´Ì³É¹¦Âʼ°·Î°©¼ì³öÂÊ
²ÉÓÃCTÒýµ¼Ïµľ­Æ¤·Î´©£¬ÒÔ¾¡¿ÉÄÜÌá¸ß·Î´©´Ì¶¨Î»µÄ׼ȷÐÔ¡£Ê¹ÓÃÇиîÕë±Èµ¥´¿´©´Ì³éÎü¸üÒ×»ñµÃ²¡Ôî×éÖ¯»î¼ì±ê±¾[2]¡£±¾ÎIJ¡ÀýʹÓÃ×Ô¶¯ÇиîÕë´©´Ì³É¹¦ÂÊ95.2%£¬ÃÖÂþÐÔ²¡Ôî×é´©´Ì³É¹¦ÂʵÍÓÚ¾ÖÏÞÐÔ²¡Ôî×飬¿ÉÄÜÓë¸Ã×鲡ÔîС¡¢ÃÖÉ¢¡¢ÃܶȵÍÓйء£ÔÚ¾ÖÏÞÐÔ²¡Ôî×éÖУ¬ÏÙ°©µÄ±ÈÀý¸ßÓÚÁÛ°©£¬¿ÉÄÜÓë¸Ã×é´ó²¿·Ö²¡ÔîλÓÚÁ½·ÎÖܱßÓйء£ÕâÓëÖÜΧÐͷΰ©ÒÔÏÙ°©¶à¼ûµÄÁÙ´²ÌØÕ÷ÏàÒ»Ö¡£
ͨ³££¬¶ÔÓڷβ¿ÖÐÑëÐ͵IJ¡Ôһ°ãÇé¿öÏÂÊ×ÏÈÑ¡ÔñÏËÎ¬Ö§Æø¹Ü¾µ¼ì²é¡£ÈôÏËÖ§¾µ¼ì²éδÄÜÈ·Õ¿É¿¼ÂǷδ©´Ì¼ì²é¡£±¾×é9Àý¾­ÏËÖ§¾µ¼ì²éδÄÜÈ·ÕïµÄ²¡Àý£¬·Î´©´Ì¾ùÈ¡µÃ³É¹¦£¬µÃµ½È·Õ˵Ã÷¶ÔÓڷβ¿ÖÐÑëÐͲ¡Ô¾­Æ¤·Î´©ÈÔÓнϴóʹÓüÛÖµ¡£
3.2·Î²¿ÃÖÂþÐÔ²¡Ôî´©´Ì³É¹¦Âʼ°·Î°©¼ì³öÂÊ
·Î²¿ÃÖÂþÐÔ²¡ÔîµÄ´©´Ì¼°²¡ÀíѧÕï¶ÏÒ»°ã½ÏÄÑ£¬Ó벡Ôî½ÏСÃÜÇÐÏà¹Ø£¬Ó°ÏìÁË´©´Ì׼ȷÐÔ¼°×éÖ¯ÌõµÄ¿É¿¿ÐÔ¡£±¾ÎÄB×éÖÐ2Àý²¡Àí½á¹ûÌáʾΪ·Î×éÖ¯ÏËά»¯¼°ÂýÐÔÑ×ϸ°û½þÈó£¬ÎªÁÙ´²Ã÷È·Õï¶ÏÌṩÁËÖØÒªÒÀ¾Ý£¬Ìáʾ¶ÔÓڷβ¿ÃÖÂþÐÔ²¡ÔCTÒýµ¼Ïµľ­Æ¤·ÎÓÐÒ»¶¨¼ÛÖµ¡£
3.3 ·Î´©´ÌµÄ°²È«ÐÔ·ÖÎö
·Î´©´ÌµÄ²¢·¢Ö¢Ö÷ÒªÓÐÆøÐØ¡¢³öѪ¡£
3.3.1 ÆøÐØ
ÆøÐØÊÇC T µ¼ÒýÏÂÐØ²¿²¡±ä»î¼ì×î³£¼ûµÄ²¢·¢Ö¢£¬·¢ÉúÂÊ10 %¡«40%[3£¬4]¡£Ó°ÏìÆøÐØ·¢ÉúÂʵÄÒòËØÒÀ´ÎÎªÐØÄ¤´©´Ì´ÎÊý¡¢´©´Ì·¾¶Í¨¹ý·Î×éÖ¯ÓÐÎÞ·ÎÆøÖ׺ʹ©´Ì·¾¶Í¨¹ýÍ¨Æø·Î×éÖ¯µÄ³¤¶È¡£±¾×鲡ÀýÆøÐØ·¢ÉúÂʽöΪ27.7%£¬ÓëÎÄÏ×±¨µÀ·¢ÉúÂÊÏà·û¡£Á½×éÆøÐØ·¢ÉúÂÊÎÞÏÔÖøÐÔ²îÒì¡£27ÀýÆøÐØ²¡Àý²¡ÔîÍâÔµ¾à±Ú²ãÐØÄ¤¾àÀë¾ù>2cm£¬5ÀýΪС²¡Ô16ÀýΪÏ·β¡Ô9ÀýΪÄêÁä´óÓÚ60ËêµÄÀÏÈË¡£·ÖÎöС²¡ÔîºÍÏ·β¡Ôî»î¼ìÆøÐØ·¢ÉúÂʸߵÄÔ­Òò£ºÐ¡²¡Ôî»î¼ì¼¼ÊõÄѶÈÔö¼Ó, ²Ù×÷ʱ¼äÏà¶Ô½Ï³¤£¬¶à´Îµ÷ÕûÕë¼â·½Ïò´´ÉËÏà¶Ô½Ï´ó£»¶øÏ·β¡ÔîËæºôÎüÒÆ¶¯¶È½Ï´ó£¬Õë¼â¶ÔÐØÄ¤µÄ´´É˽ϴó¡£ÀÏÄ겡ÀýÆøÐØ·¢ÉúÂʸߵÄÔ­Òò£¬Ö÷ÒªÊÇÓÉÓÚÀÏÄ껼Õ߷ι¦ÄÜÏà¶Ô½Ï²î£¬ÓÐʱ´©´Ì·¾¶²»¿É±ÜÃâͨ¹ý·ÎÆøÖ׵ķÎ×éÖ¯¡£
ÎÒÃÇÈÏΪ½µµÍÆøÐØ·¢ÉúÂʵĴëÊ©ÓÐÒÔϼ¸·½Ã棺£¨1£©¶£Öö»¼Õß±ÜÃâ¾çÁÒ¿ÈËÔ£¬±ØÒªÊ±Ê¹ÓÃÕò¿ÈÒ©¶ÔÖ¢´¦Àí£»£¨2£©¾¡¿ÉÄܱÜÃâ¶à´Î´©´ÌÔà²ãÐØÄ¤¼°Ò¶¼äÐØÄ¤£»£¨3£©ÕëµÀ¾¡Á¿¶Ì²¢±Ü¿ªÒ¶¼äÁÑ¡¢·Î´óÅÝ£¬¾­ÒÑʵ±äµÄ·Î×éÖ¯»òÐØÄ¤Õ³Á¬´¦½øÕ룻£¨4£©¶ÔÀÏÄ껼Õß, ÓÈÆäÊÇÓÐÂýÐÔ×èÈûÐÔ·ÎÆøÖײ¡Ê·Õß, ÊõǰӦ×Ðϸ¹Û²ì, ¾¡¿ÉÄܱܿª´©´ÌµÀÉϵķδóÅÝ»ò¾ÖÏÞÐÔ·ÎÆøÖ×£»£¨5£©Èç¹û»¼ÕßÓзβ»ÕÅ»òÐØÇ»»ýҺʱ, ¾­²»ÕŵķλòÐØÇ»»ýÒºÈë·, ´©´Ì·¾¶²»¾­¹ýÍ¨Æø·Î×éÖ¯²»»áÒýÆðÆøÐØ£»£¨6£©¾¡Á¿Ëõ¶Ì²Ù×÷ʱ¼ä¡£
3.3.2 ³öѪ
»î¼ì·Î²¡Ôî×éÖ¯£¬ÀíÂÛÉϾù»áÒýÆð¾Ö²¿³öѪ¡£³öѪÒýÁ÷µÄ;¾¶ÓÐ: ¢ÅÓÙ»ýÓÚ·Î×éÖ¯[5]£¬Ö®ºóÖð½¥ÎüÊÕ£»¢Æ¾­Ö§Æø¹ÜÅųö£»¢ÇÁ÷ÈëÐØÄ¤Ç»¡£ÊÇ·ñ³öÏÖ¿©Ñª£¬Ö÷Òª¾ö¶¨ÓÚ³öѪÊÇ·ñ¾­Ö§Æø¹ÜÅųö(¿È³ö)¡£·Î°©Ñª¹©·á¸»£¬´©´Ìºó¾Ö²¿Ò׳öÏֽ϶à³öѪ£¬´Ó¶øÒ×·¢Éú¿©Ñª¡£¿©ÑªÖÏÏ¢µÄËÀÍöÂʸߡ£µ±È»·Î´©´Ì¿©Ñª¡¢ÆøÐصķ¢ÉúÊܶàÖÖÒòËØµÄÓ°Ï죬È粡Ôλ¡¢ÐÔÖÊ¡¢·Î²¿»ù´¡¼²²¡¡¢´©´ÌÆ÷²Ä¡¢´©´Ì¼¼Êõ¡¢´©´Ì·½Ïò¼°Éî¶ÈµÈ[5.6.7]¡£
×ÜÖ®£¬CT Òýµ¼Ïµľ­Æ¤´©´Ì»î¼ì¶Ô·Î²¿²¡Ôîϸ°ûѧ¡¢×é֯ѧ±ê±¾»ñÈ¡Âʼ°Õï¶ÏÂʸߣ¬Äܹ»Ã÷È·Õï¶Ï£¬¼õÉÙÎóÕÊÇÒ»ÖÖ´´ÉËÐÔС¡¢×¼È·¡¢°²È«¡¢¾­¼ÃµÄ¼ì²é·½·¨£¬¶ÔÓÚÁÙ´²Õï¶ÏÓëÖÎÁÆ·½°¸µÄÑ¡Ôñ¾ßÓÐÖØÒªµÄÒâÒ壬µ«ÆøÐØ¡¢¿©ÑªµÈ²¢·¢Ö¢·¢ÉúµÄ·çÏÕÈÔ´æÔÚ¡£
²Î¿¼ÎÄÏ×
[1] »ÆÕñ¹ú,ÕÅÑ©ÕÜ,ÍõÎä,µÈ. CTµ¼ÒýÏ·ÎÄÚ²¡±ä´©´Ì»î¼ìÓ°ÏìÆøÐØ·¢ÉúÂÊÒòËØ·ÖÎö[J]. ÁÙ´²·ÅÉäѧÔÓÖ¾, 2003£¬22(7)£º582-585.
[2] Laurent F, Latrabe V, Vergier B, et al. CT-guided transthoracic needle biopsy of pulmonary nodules smaller than 20mm: results with an automated 20-gauge coaxial cutting needle [J]. Clin Radiol, 2000, 55(4):281-287.
[3] Yankelevitz DF, Vazquez M, Henschke CI. Special Techniques in Transthoracic Needle Biopsy of Pulmonary nodules [J]. Radiol ClinNorth Am, 2000, 38 (2):267-279.
[4] Ko J P, Shepard JO, Drucker EA, et al. Factors Influencing Pneumothorax Rate at Lung Biopsy: are Dwell Time and Angle of Pleural Puncture Contributing Factors [J]. Radiol, 2001, 220 (2):554-555.
[5] ôÃÃô½£,֣ΰÁ¼,ºúºì½Ü,µÈ. CTÒýµ¼Ï¾­Æ¤·Î´©´Ì»î¼ìµÄ°²È«ÐÔ·ÖÎö[J]. Öлª½áºËºÍºôÎüÔÓÖ¾, 2002, 25 (2) : 86-88.
[6] Charig MJ, Phillips AJ. CT-guided cutting needle biopsy of lung lesions: safty and efficacy of an outpatient service [J]. Clin Radio, 2000, 55(4): 964-969.
[7] Dennie CJ, Matzinger FR, Marriner JR, et al. Transthoracic needle biopsy of the lung: results of early discharge in 506 outpatients [J]. Radiology, 2001, 219(1): 247-251.

 




TAG: xÏß¼ÆËã»ú ´©´ÌÊõ Ìå²ãÉãÓ°Êõ »î×éÖ¯¼ì²é
 

ÆÀ·Ö£º0

ÎÒÀ´ËµÁ½¾ä

seccode

δ¾­¡¶µ±´úҽѧ¡·ÔÓÖ¾ÉçÊéÃæÍ¬Ò⣬²»µÃ×ªÔØ±¾¿¯ÎÄÕ¡£
»¶Ó­PR>4»òÈÕIP>2000µÄҽѧÀàÍøÕ¾½»»»Á´½Ó£¬QQ£º32622896
¿áվĿ¼£¬ÊÕ¼¸÷ÀàÓÅÐãÍøÕ¾